Showing results (81-90 of 109) with videos related to

Sort By:
Pageof 11
Lung Cancer (Amsterdam, Netherlands)|September 20, 2021
Real-world survey of pneumonitis and its impact on durvalumab consolidation therapy in patients with non-small cell lung cancer who received chemoradiotherapy after durvalumab approval (HOPE-005/CRIMSON)Go Saito, Yuko Oya, Yoshihiko Taniguchi, et al.
Biomed Research International|September 5, 2015
Putative Epimutagens in Maternal Peripheral and Cord Blood Samples Identified Using Human Induced Pluripotent Stem CellsYoshikazu Arai, Koji Hayakawa, Daisuke Arai, et al.
JMA Journal|August 11, 2025
Health Insurance and Its Psychosocial Correlates in Patients with Advanced Lung Cancer in JapanFumimaro Ito, Takashi Sato, Kohei Horiuchi, et al.
The Oncologist|September 12, 2021
Longitudinal Assessment of Prognostic Understanding in Patients with Advanced Lung Cancer and Its Association with Their Psychological DistressDaisuke Arai, Takashi Sato, Ichiro Nakachi, et al.
Cancer Chemotherapy and Pharmacology|January 8, 2015
A phase II study of biweekly paclitaxel and carboplatin in elderly patients with advanced non-small cell lung cancerKenzo Soejima, Katsuhiko Naoki, Kota Ishioka, et al.
Clinical Lung Cancer|August 13, 2024
Real-World Outcomes of Subsequent Chemotherapy after Progression Following Chemoradiation and Consolidative Durvalumab Therapy in Locally Advanced Non-small Cell Lung Cancer: An Exploratory Analysis from the CRIMSON Study (HOPE-005)Hayato Kawachi, Motohiro Tamiya, Yuko Oya, et al.
Lung Cancer (Amsterdam, Netherlands)|June 6, 2025
Durvalumab after concurrent chemoradiotherapy for sensitizing epidermal growth factor receptor-mutant stage III non-small cell lung cancer: A Japanese Real-World data analysisToshiya Fujisaki, Eisaku Miyauchi, Gen Kida, et al.
Clinical Lung Cancer|June 29, 2025
Osimertinib as First-Line Treatment for Patients With Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer in a Real-World Setting: Updated Overall Survival Data (OSI-FACT-OS)Yoshihiko Sakata, Go Saito, Shinya Sakata, et al.
Lung Cancer (Amsterdam, Netherlands)|September 23, 2024
Durvalumab with etoposide and carboplatin for patients with extensive-stage small cell lung cancer and interstitial lung disease: A multicenter, open-label prospective trialRyota Shibaki, Daichi Fujimoto, Eisaku Miyauchi, et al.
Lung Cancer (Amsterdam, Netherlands)|November 22, 2023
Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small cell lung cancer in a real-world setting (OSI-FACT-EP)Yoshihiko Sakata, Go Saito, Shinya Sakata, et al.
Pageof 11